Xinteza

Xinteza is an Israeli biotechnology company specializing in the biosynthetic production of high-value plant-derived compounds, with a primary focus on cannabinoids. Utilizing a proprietary microbial fermentation platform licensed from the Weizmann Institute of Science, the company produces rare and minor cannabinoids that are difficult to extract from plants in commercial quantities. Their technology enables the scalable, sustainable, and cost-effective manufacturing of pharmaceutical-grade active ingredients by engineering yeast and other microbes. Xinteza aims to provide high-purity molecules for use in therapeutic applications across various medical fields, including neurology and pain management. By bypassing traditional agricultural cultivation, the company ensures a consistent and standardized supply of complex natural molecules. Xinteza's approach positions them as a key supplier and partner for pharmaceutical companies developing cannabinoid-based medicines.